Literature DB >> 28131740

Adipose tissue is influenced by hypoxia of obstructive sleep apnea syndrome independent of obesity.

C E Thorn1, B Knight2, E Pastel2, L J McCulloch2, B Patel3, A C Shore1, K Kos4.   

Abstract

AIMS: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular risk and diabetes independent of obesity. We investigated whether adipose tissue dysfunction is exacerbated due to increased tissue hypoxia.
METHODS: Adipose tissue (AT) oxygenation was measured with a Clarke-type electrode (pATO2) in 16 men with OSAS before and after 4 months of continuous positive airway pressure therapy (CPAP) and in BMI-matched controls. Oxygenation was simultaneously monitored in arterial blood by pulse oximetry (SaO2); mixed blood in AT microcirculation by reflectance spectroscopy (SATO2) along with blood flow. Markers of hypoxia, adipo- and angiogenesis, inflammation and fibrosis were analysed in AT and serum.
RESULTS: OSAS subjects were more insulin resistant. Despite lower arterial SaO2 (95.4±1.3% vs. 97.1±1.6%, P=0.013) in subjects with OSAS, there was no difference in the oxygen content of AT microcirculation (61.6±18.4 vs. 72.2±7.0%, P=0.07) or pATO2 (49.2±7.5 vs. 50.4±14.7mmHg, P=0.83) between groups. Resting AT blood flow was higher in OSAS compared to controls (108.5±22.7 vs. 78.9±24.9au, P<0.005) and strongly associated with inflammation markers IL-6 and MCP-1. AT of OSAS subjects showed increased inflammation (TNFA P=0.049) and fibrosis (COL3A1 P=0.02), a trend of higher HIF1A expression (P=0.06) and reduced adipogenesis (PPARG P=0.006). After CPAP, only expression of the lipid deposition marker LPL increased (30%, P=0.047).
CONCLUSIONS: Adipose tissue of awake OSAS subjects appears no more hypoxic than adipose tissue of BMI-matched controls despite daytime hypoxaemia. Increased adipose tissue blood flow may be explained by an increased inflammatory response. We observe features of adipose dysfunction in subjects with OSAS, which attribute to increased cardiometabolic risk associated with this condition.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adipose tissue; Hypoxia; Obesity; Obstructive sleep apnea syndrome

Mesh:

Substances:

Year:  2017        PMID: 28131740     DOI: 10.1016/j.diabet.2016.12.002

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  7 in total

1.  Obesity, sleep apnea, and cancer.

Authors:  Isaac Almendros; Miguel A Martinez-Garcia; Ramon Farré; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-18       Impact factor: 5.095

2.  Obesity and Obstructive Sleep Apnea.

Authors:  Maria R Bonsignore
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Effect of obstructive sleep apnea on glucose metabolism.

Authors:  Han-Chow E Koh; Stephan van Vliet; Chao Cao; Bruce W Patterson; Dominic N Reeds; Richard Laforest; Robert J Gropler; Yo-El S Ju; Bettina Mittendorfer
Journal:  Eur J Endocrinol       Date:  2022-02-23       Impact factor: 6.558

4.  Evaluation of Serum and Plasma Interleukin-6 Levels in Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression.

Authors:  Mohammad Moslem Imani; Masoud Sadeghi; Habibolah Khazaie; Mostafa Emami; Dena Sadeghi Bahmani; Serge Brand
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 5.  Effects of Intermittent Hypoxia on Cytokine Expression Involved in Insulin Resistance.

Authors:  Tomoko Uchiyama; Hiroyo Ota; Chiho Ohbayashi; Shin Takasawa
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

6.  Influence of body mass index on postoperative complications after thymectomy in myasthenia gravis patients.

Authors:  Xu-Dong Liu; Ming-Rui Shao; Lei Sun; Lin Zhang; Xin-Shan Jia; Wen-Ya Li
Journal:  Oncotarget       Date:  2017-07-12

Review 7.  Technical Feasibility and Physiological Relevance of Hypoxic Cell Culture Models.

Authors:  Jiri Pavlacky; Jan Polak
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-21       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.